• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Apollomics Inc.

    12/22/25 4:30:49 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APLM alert in real time by email
    6-K
    false2025Q2--12-310001944885June 30, 20250001944885ifrs-full:TopOfRangeMember2025-01-012025-06-300001944885aplm:InitialSupplyOfDrugProductMember2025-01-012025-06-300001944885aplm:LicensePerformanceObligationMember2025-01-012025-06-300001944885aplm:ClassAOrdinarySharesMemberaplm:TwoThousandAndTwentyThreeIncentiveAwardPlanMember2025-06-300001944885ifrs-full:PreferenceSharesMember2023-12-310001944885ifrs-full:RetainedEarningsMember2024-01-012024-06-300001944885aplm:ClassBOrdinarySharesMember2025-06-300001944885ifrs-full:ReserveOfSharebasedPaymentsMember2023-12-310001944885aplm:ProjectMaxSpacMergerSubIncMember2025-01-012025-06-300001944885ifrs-full:IssuedCapitalMember2025-06-300001944885aplm:SubsequentEventsMember2025-10-012025-10-310001944885aplm:SettlementAgreementMember2025-01-012025-06-3000019448852025-01-012025-06-300001944885aplm:PennyWarrantsMemberaplm:PipeSubscriptionAgreementMemberifrs-full:Level3OfFairValueHierarchyMember2025-06-300001944885ifrs-full:TopOfRangeMember2024-06-300001944885ifrs-full:BottomOfRangeMember2024-06-300001944885ifrs-full:PreferenceSharesMember2024-12-310001944885ifrs-full:SharePremiumMember2025-06-300001944885ifrs-full:RetainedEarningsMember2024-06-300001944885ifrs-full:ReserveOfSharebasedPaymentsMember2025-01-012025-06-3000019448852023-12-310001944885ifrs-full:BottomOfRangeMemberaplm:TwoThousandAndSixteenPlanMember2025-01-012025-06-300001944885ifrs-full:RestrictedShareUnitsMemberaplm:TwoThousandTwentyThreePlanMember2025-06-300001944885ifrs-full:ReserveOfSharebasedPaymentsMember2024-12-310001944885aplm:PipeSubscriptionAgreementMember2025-09-020001944885ifrs-full:GrossCarryingAmountMember2024-12-310001944885aplm:ClassAOrdinarySharesMember2025-06-300001944885country:CN2025-06-300001944885ifrs-full:IssuedCapitalMember2023-12-310001944885ifrs-full:SharePremiumMember2024-12-310001944885ifrs-full:IssuedCapitalMember2024-01-012024-06-300001944885ifrs-full:TopOfRangeMemberaplm:TwoThousandAndSixteenPlanMember2025-01-012025-06-300001944885aplm:LaunXPInternationalMember2025-03-012025-03-310001944885ifrs-full:SharePremiumMember2024-01-012024-06-300001944885aplm:TwoThousandAndSixteenPlanMember2024-01-012024-06-300001944885aplm:ZhejiangCrownBochuangBiopharmaCoLtdMember2025-01-012025-06-300001944885aplm:LessThanOneYearMember2025-06-300001944885ifrs-full:RestrictedShareUnitsMemberaplm:TwoThousandTwentyThreePlanMember2024-01-012024-06-300001944885ifrs-full:ShareOptionsMember2024-01-012024-06-300001944885ifrs-full:IssuedCapitalMember2024-06-300001944885aplm:LicensePerformanceObligationMember2025-06-3000019448852024-12-310001944885aplm:PennyWarrantsMemberaplm:PipeSubscriptionAgreementMemberifrs-full:Level3OfFairValueHierarchyMember2025-01-012025-06-300001944885ifrs-full:IssuedCapitalMember2025-01-012025-06-300001944885ifrs-full:OrdinarySharesMember2024-06-300001944885aplm:TwoThousandAndSixteenPlanMemberaplm:RestrictedShareAwardsMember2025-01-012025-06-300001944885ifrs-full:RetainedEarningsMember2025-06-300001944885ifrs-full:TopOfRangeMember2025-06-300001944885ifrs-full:PreferenceSharesMember2025-06-300001944885ifrs-full:RetainedEarningsMember2024-12-3100019448852025-06-300001944885aplm:TimeBasedShareOptionsMemberaplm:TwoThousandAndSixteenPlanMember2025-01-012025-06-300001944885aplm:PrivateWarrantsMemberaplm:MaxproCapitalAcquisitionCorpMemberifrs-full:Level2OfFairValueHierarchyMember2024-12-310001944885ifrs-full:OrdinarySharesMember2023-12-310001944885aplm:TwoThousandAndSixteenPlanMember2024-06-300001944885aplm:PublicWarrantsMemberaplm:MaxproCapitalAcquisitionCorpMemberifrs-full:Level1OfFairValueHierarchyMember2024-12-310001944885aplm:PublicWarrantsMemberaplm:MaxproCapitalAcquisitionCorpMemberifrs-full:Level1OfFairValueHierarchyMember2025-01-012025-06-300001944885ifrs-full:BottomOfRangeMemberaplm:TwoThousandAndSixteenPlanMember2025-06-300001944885ifrs-full:OrdinarySharesMember2024-12-310001944885ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2024-12-310001944885aplm:PennyWarrantsMember2024-01-012024-06-300001944885aplm:TwoThousandAndSixteenPlanMemberaplm:ShareAppreciationRightsrestrictedShareUnitAwardsAndOtherAwardsMember2025-01-012025-06-300001944885aplm:ApollomicsIncMember2025-01-012025-06-300001944885ifrs-full:ReserveOfSharebasedPaymentsMember2024-01-012024-06-300001944885aplm:TwoThousandAndSixteenPlanMember2025-06-300001944885aplm:UnvestedRestrictedSharesMember2024-01-012024-06-300001944885aplm:TwoThousandAndSixteenPlanMember2024-12-310001944885aplm:ApollomicsHongKongLimitedMember2025-01-012025-06-300001944885aplm:ApollomicsAustraliaPtyLtdMember2025-01-012025-06-3000019448852024-06-300001944885country:CN2024-12-310001944885aplm:PublicWarrantsMemberaplm:MaxproCapitalAcquisitionCorpMemberifrs-full:Level1OfFairValueHierarchyMember2025-06-300001944885ifrs-full:RestrictedShareUnitsMemberaplm:TwoThousandTwentyThreePlanMember2024-12-310001944885aplm:LaunXPInternationalMember2025-01-012025-06-300001944885ifrs-full:TopOfRangeMemberaplm:TwoThousandAndSixteenPlanMember2025-06-300001944885aplm:ClassBOrdinarySharesMember2024-12-3100019448852024-01-012024-06-300001944885ifrs-full:GrossCarryingAmountMember2025-06-300001944885aplm:ApollomicsPrivateWarrantsMember2025-01-012025-06-300001944885aplm:TwoThousandAndSixteenPlanMemberaplm:RestrictedShareAwardsMember2024-01-012024-06-300001944885aplm:ClassBOrdinarySharesMember2023-12-310001944885aplm:SettlementAgreementMemberaplm:SubsequentEventsMember2025-11-192025-11-190001944885aplm:ApollomicsPublicWarrantsMember2024-01-012024-06-300001944885aplm:ClassAOrdinarySharesMember2024-06-300001944885aplm:ClassAOrdinarySharesMember2025-01-012025-06-300001944885ifrs-full:RestrictedShareUnitsMemberaplm:TwoThousandTwentyThreePlanMember2025-01-012025-06-300001944885ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2025-06-300001944885aplm:ApollomicsPrivateWarrantsMember2024-01-012024-06-300001944885ifrs-full:ReserveOfSharebasedPaymentsMember2024-06-300001944885ifrs-full:ShareOptionsMember2025-01-012025-06-300001944885ifrs-full:BottomOfRangeMember2025-01-012025-06-300001944885aplm:PipeSubscriptionAgreementMember2025-09-022025-09-020001944885ifrs-full:BottomOfRangeMember2025-06-300001944885aplm:PennyWarrantsMember2025-01-012025-06-300001944885ifrs-full:RetainedEarningsMember2023-12-310001944885aplm:ClassAOrdinarySharesMember2023-12-310001944885aplm:TwoThousandAndSixteenPlanMemberaplm:ShareAppreciationRightsrestrictedShareUnitAwardsAndOtherAwardsMember2024-01-012024-06-300001944885aplm:TwoThousandAndSixteenPlanMemberaplm:RestrictedShareAwardsMember2025-06-300001944885aplm:InitialSupplyOfDrugProductMember2025-06-300001944885ifrs-full:RestrictedShareUnitsMemberaplm:TwoThousandTwentyThreePlanMember2024-06-300001944885aplm:UnvestedRestrictedSharesMember2025-01-012025-06-300001944885aplm:OtherReserveExcluedingShareBasedPaymentReserveMember2024-12-310001944885aplm:ClassAOrdinarySharesMember2024-01-012024-06-300001944885aplm:TwoThousandAndSixteenPlanMemberifrs-full:ShareOptionsMember2025-01-012025-06-300001944885ifrs-full:ReserveOfSharebasedPaymentsMember2025-06-300001944885aplm:OneToTwoYearsMember2025-06-300001944885aplm:ZhejiangCrownmabBiotechCoLtdMember2025-01-012025-06-300001944885aplm:OtherReserveExcluedingShareBasedPaymentReserveMember2024-06-300001944885aplm:ClassAOrdinarySharesMemberaplm:PipeSubscriptionAgreementMember2025-09-020001944885aplm:ThreeToFiveYearsMember2025-06-300001944885aplm:ApollomicsPublicWarrantsMember2025-01-012025-06-300001944885ifrs-full:RestrictedShareUnitsMemberaplm:TwoThousandTwentyThreePlanMember2023-12-310001944885aplm:TwoThousandAndSixteenPlanMember2025-01-012025-06-300001944885ifrs-full:RetainedEarningsMember2025-01-012025-06-300001944885aplm:ClassAOrdinarySharesMember2024-12-310001944885aplm:ClassBOrdinarySharesMember2024-06-300001944885ifrs-full:SharePremiumMember2024-06-300001944885aplm:PennyWarrantsMemberaplm:PipeSubscriptionAgreementMemberifrs-full:Level3OfFairValueHierarchyMember2024-12-310001944885aplm:PrivateWarrantsMemberaplm:MaxproCapitalAcquisitionCorpMemberifrs-full:Level2OfFairValueHierarchyMember2025-01-012025-06-300001944885aplm:OtherReserveExcluedingShareBasedPaymentReserveMember2023-12-310001944885aplm:SettlementAgreementMember2025-06-3000019448852024-11-142024-11-140001944885aplm:OtherReserveExcluedingShareBasedPaymentReserveMember2025-06-300001944885ifrs-full:IssuedCapitalMember2024-12-310001944885ifrs-full:SharePremiumMember2023-12-310001944885aplm:MoreThanFiveYearsMember2025-06-300001944885aplm:PrivateWarrantsMemberaplm:MaxproCapitalAcquisitionCorpMemberifrs-full:Level2OfFairValueHierarchyMember2025-06-300001944885aplm:TwoThousandAndSixteenPlanMember2023-12-310001944885ifrs-full:PreferenceSharesMember2024-06-300001944885ifrs-full:OrdinarySharesMember2025-06-30xbrli:purexbrli:sharesaplm:PerformanceObligationsiso4217:USDutr:Yiso4217:USDxbrli:shares

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the Month of December 2025

    Commission File Number: 001-41670

     

     

    Apollomics Inc.

    (Translation of registrant’s name into English)

     

    989 E. Hillsdale Blvd., Suite 220

    Foster City, CA 94404

    Telephone: (650) 209-4055

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

    Form 20-F ☒ Form 40-F ☐

     

     


     

    EXPLANATORY NOTE

     

    On December 22, 2025, Apollomics Inc. (the “Company”) issued unaudited condensed consolidated interim financial statements for the six months ended June 30, 2025 and management’s discussion and analysis of financial condition and results of operations (the “MD&A”) for the six months ended June 30, 2025. A copy of such unaudited condensed consolidated interim financial statements is attached hereto as Exhibit 99.1. A copy of the MD&A is attached hereto as Exhibit 99.2.

    On December 22, 2025, the Company issued a press release in which the Company reported its financial results for the six months ended June 30, 2025. A copy of such press release is furnished as Exhibit 99.3 hereto.

    The information furnished in Exhibit 99.1 and Exhibit 99.2 to this Report of Foreign Private Issuer on Form 6-K (this “Report”) shall be deemed to be filed with the Securities and Exchange Commission and incorporated by reference into the Company’s registration statements on Form S-8 (File No. 333-272559) and Form F-3 (File Nos. 333-278430, 333-278431 and 333-279549), and any related prospectuses, as such registration statements and prospectuses may be amended from time to time, and to be a part thereof from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

    APPLICATION OF HOME COUNTRY PRACTICE RULES

     

    The Company is a “foreign private issuer” (as such term is defined in Rule 3b-4 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) and the Company’s Class A ordinary shares, par value $0.01 per share (each a “Class A Ordinary Share”), and warrants are listed on the Nasdaq Capital Market. As a foreign private issuer, the Company is permitted under Nasdaq rules to follow home country governance practices instead of certain Nasdaq requirements pursuant to Nasdaq Rule 5615(a)(3). As disclosed in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2024, as filed with the U.S. Securities and Exchange Commission on April 3, 2025 (the “Annual Report”), the Company follows home country corporate governance practices instead of certain Nasdaq corporate governance requirements, as described in more detail therein. The Company has also informed Nasdaq that it intends to follow home country governance practices in lieu of shareholder approval requirements in Nasdaq Rule 5635, and that it will disclose in its annual report on Form 20-F for the fiscal year ended December 31, 2025 each requirement that it does not follow and describe the home country practices it follows in lieu of such requirements.

     

     


     

    EXHIBIT INDEX

     

    Exhibit No.

     

    Description

    99.1

     

    Unaudited Condensed Consolidated Interim Financial Statements for the Six Months Ended June 30, 2025 and 2024, and as of June 30, 2025 and December 31, 2024

    99.2

     

    Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Six Months Ended June 30, 2025 and 2024

    99.3

     

    Press release dated December 22, 2025

    101

     

    Interactive Data File (formatted as Inline XBRL)

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     


     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

    Apollomics Inc.

    Date: December 22, 2025

    By:

    /s/ Hung Wen (Howard) Chen

    Name

    Hung Wen (Howard) Chen

    Title:

    Chief Executive Officer

     

     


    Get the next $APLM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APLM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APLM
    SEC Filings

    View All

    SEC Form S-8 filed by Apollomics Inc.

    S-8 - Apollomics Inc. (0001944885) (Filer)

    2/2/26 5:30:58 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Apollomics Inc.

    6-K - Apollomics Inc. (0001944885) (Filer)

    12/22/25 4:30:49 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Apollomics Inc.

    6-K - Apollomics Inc. (0001944885) (Filer)

    12/12/25 11:35:36 AM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    Financials

    Live finance-specific insights

    View All

    Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

    Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China – topline data expected in the first half of 2025$37.8 million in cash, cash equivalents and money market funds as of December 31, 2023, with a cash runway through first quarter 2025Management to host conference call today, Thursday, March 28, 2024 at 8:30 a.m. ET FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) --  Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-

    3/28/24 7:00:00 AM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024

    FOSTER CITY, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that the Company will report full year 2023 financial results on Thursday, March 28, 2024, before the opening of the U.S. financial markets. Apollomics' management team will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The conference call will be available on Apollomics' website, www.apollomicsinc.com, under the Investors section and will be archived there for approximately 90 days. The co

    3/26/24 8:00:00 AM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

    Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023 Approximately $52.6 million in cash, cash equivalents, and investments at June 30, 2023; Cash runway to mid-year 2024 Debuted as a publicly traded targeted oncology company March 30, 2023 Management to host conference call Monday, October 2, 2023 at 8:30 a.m. ET FOSTER CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) --  Apollomics Inc. (NASDAQ:APLM) (the "Company"), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today annou

    9/28/23 4:17:57 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Apollomics Reports First Half 2025 Financial Results

    FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2025 ended June 30, 2025. First Half 2025 Financial Results Ended June 20, 2025 Cash, cash equivalents, bank deposits and money market funds as of June 30, 2025, were $2.1 million, compared to $9.8 million as of December 31, 2024. Based on current projections, the Company believes its cash position is sufficient to fund planned operations into the third quarter of

    12/22/25 4:05:00 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollomics Announces Settlement of Cayman Litigation

    FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company") (NASDAQ:APLM) announced today entering into a settlement agreement (the "Settlement Agreement" or the "Agreement") with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, "TWVC"), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the "Cayman Litigation"). The Cayman Litigation involved claims by two minority shareholders relating to the requested redemption of preferred shares of the Company before the consummation of the Company's merger with Maxp

    11/19/25 5:38:35 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apollomics Announces Changes to its Board of Directors and Composition of Committees

    FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company's board of directors ("Board") and composition of committees. On November 16, 2025, Mr. Po-Jen Hsueh resigned from the Board. Mr. Hsueh's resignation was not related to any disagreement with the Company. Pursuant to a meeting of the Board on November 16, 2025, Dr. Ya-Chi (Claudia) Huang was appointed to the Board to fill the vacancy resulting from Mr. Hsueh's resignation. Dr. Ya-Chi (Claudia) Huang will also replace Mr. Po-Jen Hsueh as a

    11/17/25 11:00:00 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Apollomics Inc.

    SC 13D/A - Apollomics Inc. (0001944885) (Subject)

    8/15/24 4:38:25 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Apollomics Inc. (Amendment)

    SC 13G/A - Apollomics Inc. (0001944885) (Subject)

    5/30/24 4:15:08 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Apollomics Inc. (Amendment)

    SC 13D/A - Apollomics Inc. (0001944885) (Subject)

    5/22/24 7:32:01 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLM
    Leadership Updates

    Live Leadership Updates

    View All

    Apollomics, Inc. Company Operational Continuity Update

    FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), today announced the following company operational update. Apollomics is a clinical-stage biotechnology company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. With a pipeline of nine product candidates across 11 programs, including six in clinical development, the Company is focused on tackling some of the most challenging cancers, such as lung cancer, brain cancer, and other solid tumors. Apollomics' strategic approach combines targeted therapies, immuno-oncology, and novel mechanisms of action designed to

    10/13/25 9:22:37 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care